哥伦比亚长老会研究人员展示前列腺癌药物显着抑制肿瘤生长，副作用最小

临床试验结果在泌尿外科杂志上发表

2001年8月8日纽约纽约 - 临床研究的结果，对exisulind的影响，一种新的药物被显示为具有晚期前列腺癌的男性缓慢肿瘤生长，正在发表于9月期刊期刊上发表泌尿外科。该研究是首先表现出一类新的药物的重要效果，这些药物可能稳定晚期前列腺癌患者患者患者。“这些结果表明，渗透急性前列腺癌中的男性可能会延迟疾病进展，”哥伦比亚大学医师院长泌尿科泌尿科助理泌尿科助理教授博士说，泌尿外科州的泌尿外科州犹太人医院泌尿科主任，和审判的主要调查人员。“这将随后延长手术后PSA的时间段和雄激素剥夺疗法的需要。”exisulind来自一类叫做选择性凋亡抗肿瘤药物（桑兰人）的新类化合物。索兰斯抑制环状GMP磷酸二酯酶，并选择性地诱导细胞凋亡（编程细胞死亡）在异常生长的癌前癌症和癌细胞中。因为SAANDs不诱导正常细胞中的细胞凋亡，它们不产生大部分的不良反应或严重的副作用通常与用于治疗癌症的化学治疗剂相关的。其他可用的治疗，如药物，激素，或辐射，尽量的疾病和提高生存时间限制传播通过缩小或稳定肿瘤，但可能会损害与严重的副作用，患者的恢复。 “For instance, hormonal therapy produces high response rates in metastatic prostate cancer, but patients develop resistance over time,” says Dr. Goluboff. “The side effects of hormonal treatment can significantly impact the patient’s quality of life. New treatment options that might delay the need for such side effect-prone therapies could provide great benefit in the management of prostate cancer.” Previous studies in mice showed that Exisulind inhibits the growth of prostate cancer by 80 percent to 90 percent. In a related study of patients, researchers found that the drug also causes regression in the growth of precancerous colonic polyps, a condition that often leads to colon cancer. For 12 months, the trial followed 96 prostate cancer patients who already had their prostate glands removed. All had rising prostate-specific antigen (PSA) levels indicating recurrent disease. Half received Exisulind, and half were given a placebo. The researchers measured the drug's ability to slow or halt disease progression by following patients' PSA levels. High levels of PSA are associated with more aggressive disease. Imaging tests were performed before and after the study. All of the men were classified into risk groups with no statistical difference in age, race, and weight. The study showed a significant decrease in the rate of rise in PSA in patients given Exisulind compared with placebo. Almost 185,000 new cases of prostate cancer will be diagnosed in the United States this year. More than 39,000 men will die of the disease, making it the second leading cause of cancer death in men. Although prognosis is good when prostate cancer is detected early, advanced disease, while treatable, has no cure. Dr. Goluboff cautions that more research needs to be conducted to determine long-term effects in these patients and in other groups of patients with prostate cancer. The study was funded by Cell Pathways Inc., developer of the drug Exisulind. The company first announced the results of the trial in November 1999.

###